Cancer biotech Rondo launches with $67M in funding

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs Rondo Therapeutics is developing bispecific antibody drugs capable of treating solid tumors, which have eluded this type of cancer therapy. Led by co-founders and Teneobio veterans Shelley Force Aldred and Nathan Trinklein, the biotech startup has emerged from stealth backed by a $67 million Series A round of funding. SPONSORED Diversity through accessibility: How in-home clinical trials can enroll more patients of color From Workpath & MedCity News Clinical trials have long struggled to enroll participants that reflect the demographics of a patient population, but new models can change that. AI to help bridge care gap between visits for high risk patients By Emma Bardin Saturday, March 5, 2022 10:23 PM Healthcare technology company WellSky acquired TapCloud, a virtual engagement technology company that connects patients and providers in real-time to address care needs between visits, leveraging AI. Read more » MedCity INVEST 2022   MedCity INVEST 2022 at The Ritz Carlton Chicago is a 3 day gathering with numerous opportunities for in-person networking and learning around the latest technologies and investment trends from VCs and successful entrepreneurs.   Register Now MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails